
## David W Scheifele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/516177/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women. JAMA - Journal of the American Medical Association, 2013, 309, 1793.	7.4	352
2	Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgaryâ€Area <i>Streptococcus pneumoniae</i> Research (CASPER) Study. Clinical Infectious Diseases, 2009, 49, 205-212.	5.8	161
3	Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. Journal of Pediatrics, 2003, 143, 576-581.	1.8	156
4	Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. Journal of General Virology, 2006, 87, 641-650.	2.9	145
5	Epidemiological Features of Pertussis in Hospitalized Patients in Canada, 1991â€1997: Report of the Immunization Monitoring Program–Active (IMPACT). Clinical Infectious Diseases, 1999, 28, 1238-1243.	5.8	142
6	Rapid diagnosis of Hemophilus influenzae type b infections by latex particle agglutination and counterimmunoelectrophoresis. Journal of Pediatrics, 1978, 93, 37-42.	1.8	133
7	Maternal immunisation: collaborating with mother nature. Lancet Infectious Diseases, The, 2017, 17, e197-e208.	9.1	133
8	School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet, The, 2000, 355, 549-550.	13.7	121
9	Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. Pediatrics, 2003, 112, e348-e348.	2.1	93
10	The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine, 2010, 28, 2130-2136.	3.8	92
11	Invasive Pneumococcal Infections in Canadian Children, 1991-1998: Implications for New Vaccination Strategies. Clinical Infectious Diseases, 2000, 31, 58-64.	5.8	91
12	Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infectious Diseases, The, 2017, 17, e209-e222.	9.1	89
13	Hospitalization for Influenza A Versus B. Pediatrics, 2016, 138, .	2.1	86
14	Surveillance for Influenza Admissions Among Children Hospitalized in Canadian Immunization Monitoring Program Active Centers, 2003-2004. Pediatrics, 2006, 118, e610-e619.	2.1	81
15	Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine, 2013, 32, 124-130.	3.8	81
16	Increasing incidence of ampicillin resistance in Hemophilus influenzae. Journal of Pediatrics, 1978, 92, 889-892.	1.8	78
17	Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatric Infectious Disease Journal, 2000, 19, 276-283.	2.0	76
18	Invasive Infections Caused by Haemophilus influenzae Serotypes in Twelve Canadian IMPACT Centers, 1996–2001. Pediatric Infectious Disease Journal, 2007, 26, 1025-1031.	2.0	71

#	Article	IF	CITATIONS
19	Cortisol, Behavior, and Heart Rate Reactivity to Immunization Pain at 4 Months Corrected Age in Infants Born Very Preterm. Clinical Journal of Pain, 2010, 26, 698-704.	1.9	68
20	Outcomes of Invasive Meningococcal Disease in Adults and Children in Canada Between 2002 and 2011: A Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, e27-e35.	5.8	67
21	Progress in the prevention of pneumococcal infection. Cmaj, 2005, 173, 1149-1151.	2.0	66
22	Effects of Routine Infant Vaccination With the 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Streptococcus pneumoniae in Children in Calgary, Canada. Pediatric Infectious Disease Journal, 2008, 27, 526-532.	2.0	65
23	The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada. Pediatric Infectious Disease Journal, 2009, 28, 220-224.	2.0	65
24	Pandemic influenza in Canadian children: A summary of hospitalized pediatric cases. Vaccine, 2010, 28, 3180-3184.	3.8	63
25	Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatric Infectious Disease Journal, 1994, 13, 348-355.	2.0	60
26	Serious Adverse Events Associated with Bacille Calmette-Guérin Vaccine in Canada. Pediatric Infectious Disease Journal, 2005, 24, 538-541.	2.0	59
27	Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months. Pediatrics, 2011, 128, e276-e289.	2.1	56
28	The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada. Pediatric Infectious Disease Journal, 2013, 32, e20-e25.	2.0	56
29	Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health, 2014, 14, 442.	2.9	55
30	Endotoxinemia and Thrombocytopenia during Neonatal Necrotizing Enterocolitis. American Journal of Clinical Pathology, 1985, 83, 227-229.	0.7	54
31	Influenza vaccination in paediatric nurses: Cross-sectional study of coverage, refusal, and factors in acceptance. Vaccine, 2008, 26, 2942-2948.	3.8	54
32	Ventricular involvement in experimental Hemophilus influenzae meningitis. Journal of Pediatrics, 1978, 93, 927-930.	1.8	52
33	Immunization monitoring program, active: a model of active surveillance of vaccine safety. Seminars in Pediatric Infectious Diseases, 2003, 14, 213-219.	1.7	52
34	Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatric Infectious Disease Journal, 2003, 22, 119-122.	2.0	51
35	Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine, 2001, 19, 4720-4726.	3.8	50
36	Ampicillin-Resistant Haemophilus influenzae Colonizing Ambulatory Children. American Journal of Diseases of Children, 1981, 135, 406.	0.5	48

#	Article	IF	CITATIONS
37	The Effect of Funded Varicella Immunization Programs on Varicella-related Hospitalizations in IMPACT Centers, Canada, 2000–2008. Pediatric Infectious Disease Journal, 2012, 31, 956-963.	2.0	48
38	Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada. Pediatric Infectious Disease Journal, 2012, 31, 72-77.	2.0	48
39	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	3.8	47
40	Otitis media caused by non-typable, ampicillin-resistant strains of Haemophilus influenzae. Journal of Pediatrics, 1976, 88, 646-649.	1.8	45
41	Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatric Infectious Disease Journal, 2002, 21, 903-909.	2.0	45
42	A Modified Vaccine Reduces the Rate of Large Injection Site Reactions to the Preschool Booster Dose of Diphtheria-Tetanus-Acellular Pertussis Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 1059-1066.	2.0	45
43	The Effect of Changing From Whole-Cell to Acellular Pertussis Vaccine on the Epidemiology of Hospitalized Children With Pertussis in Canada. Pediatric Infectious Disease Journal, 2007, 26, 31-35.	2.0	45
44	Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatric Infectious Disease Journal, 1999, 18, 772-779.	2.0	45
45	Lack of Evidence of Encephalopathy Related to Pertussis Vaccine : Active Surveillance by IMPACT, Canada, 1993–2002. Pediatric Infectious Disease Journal, 2004, 23, 568-571.	2.0	44
46	Role of bacterial toxins in neonatal necrotizing enterocolitis. Journal of Pediatrics, 1990, 117, S44-S46.	1.8	43
47	Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine, 2003, 21, 2298-2306.	3.8	43
48	Ocular and Respiratory Symptoms Attributable to Inactivated Split Influenza Vaccine: Evidence from a Controlled Trial Involving Adults. Clinical Infectious Diseases, 2003, 36, 850-857.	5.8	43
49	Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Human Vaccines and Immunotherapeutics, 2013, 9, 2460-2473.	3.3	43
50	The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatric Infectious Disease Journal, 2000, 19, 1053-1059.	2.0	41
51	Injection-Site Reactions to Booster Doses of Acellular Pertussis Vaccine: Rate, Severity, and Anticipated Impact. Pediatrics, 2003, 112, e453-e459.	2.1	41
52	Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. Cmaj, 2005, 172, 53-56.	2.0	39
53	Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine, 2006, 24, 2057-2064.	3.8	38
54	The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012. Clinical Infectious Diseases, 2014, 59, 1208-1215.	5.8	38

#	Article	IF	CITATIONS
55	Comparison of two antibiotic regimens for neonatal necrotizing enterocolitis. Journal of Antimicrobial Chemotherapy, 1987, 20, 421-429.	3.0	37
56	Neonatal necrotizing enterocolitis associated with delta toxin-producing methicillin-resistant Staphylococcus aureus. Pediatric Infectious Disease Journal, 1990, 9, 88-91.	2.0	37
57	Epidemiology of Pertussis and Haemophilus influenzae type b Disease in Canada With Exclusive Use of a Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus-Haemophilus influenzae type b Pediatric Combination Vaccine and an Adolescent-Adult Tetanus-Diphtheria-Acellular Pertussis Vaccine. Pediatric Infectious Disease Journal, 2009, 28, 521-528.	2.0	37
58	Prevalence of Toll-like receptor signalling defects in apparently healthy children who developed invasive pneumococcal infection. Clinical Immunology, 2007, 122, 271-278.	3.2	35
59	Substantial Morbidity for Hospitalized Children With Community-Acquired Rotavirus Infections. Pediatric Infectious Disease Journal, 2010, 29, 879-882.	2.0	35
60	Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review. BMC Infectious Diseases, 2005, 5, 56.	2.9	34
61	ADVERSE NEUROLOGIC REACTIONS AFTER BOTH DOSES OF PANDEMIC H1N1 INFLUENZA VACCINE WITH OPTIC NEURITIS AND DEMYELINATION. Pediatric Infectious Disease Journal, 2011, 30, 84-86.	2.0	34
62	Burden of Seasonal Influenza in Children With Neurodevelopmental Conditions. Pediatric Infectious Disease Journal, 2014, 33, 710-714.	2.0	33
63	Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine, 1992, 10, 455-460.	3.8	31
64	Detection of Human Influenza Virus in the Stool of Children. Pediatric Infectious Disease Journal, 2006, 25, 1194-1195.	2.0	31
65	Evaluation of the Limulus test for endotoxemia in neonates with suspected sepsis. Journal of Pediatrics, 1981, 98, 899-903.	1.8	30
66	Comparison of Children Hospitalized With Seasonal Versus Pandemic Influenza A, 2004–2009. Pediatrics, 2012, 130, 397-406.	2.1	30
67	Lack of Nosocomial Spread of Varicella in a Pediatric Hospital with Negative Pressure Ventilated Patient Rooms. Infection Control, 1985, 6, 120-121.	0.1	28
68	Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Human Vaccines and Immunotherapeutics, 2017, 13, 2048-2057.	3.3	28
69	Odontogenic infections. Pediatric Infectious Disease Journal, 1984, 3, 257-265.	2.0	27
70	Incidence of ampicillin-resistant Hemophilus influenzae in otitis media. Journal of Pediatrics, 1976, 89, 839-841.	1.8	26
71	Spontaneous Endotoxinemia in Premature Infants. Journal of Pediatric Gastroenterology and Nutrition, 1985, 4, 67-74.	1.8	24
72	Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. Clinical Infectious Diseases, 2003, 37, 1059-1066.	5.8	24

#	Article	IF	CITATIONS
73	Safety and immunogenicity of a measles–mumps–rubella–varicella vaccine given as a second dose in children up to six years of age. Vaccine, 2009, 27, 2701-2706.	3.8	24
74	Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children. Pediatric Infectious Disease Journal, 2011, 30, 402-407.	2.0	23
75	Nationwide Canadian Study of Hepatitis A Antibody Prevalence Among Children Eight to Thirteen Years Old. Pediatric Infectious Disease Journal, 2005, 24, 514-519.	2.0	22
76	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1 <sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials, 2012, 13, 23-32.	2.0	22
77	Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine, 1996, 14, 1399-1406.	3.8	21
78	Three-Year Follow-Up of protection Rates in Children Given Varicella Vaccine. Canadian Journal of Infectious Diseases & Medical Microbiology, 2002, 13, 382-286.	0.3	21
79	Evaluation of Skin Antisepsis Prior to Blood Culture in Neonates. Infection Control, 1984, 5, 489-491.	0.1	20
80	POSTVACCINATION THROMBOCYTOPENIA IN CANADA. Pediatric Infectious Disease Journal, 2010, 29, 559-561.	2.0	20
81	Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatric Infectious Disease Journal, 2002, 21, 947-950.	2.0	19
82	Pediatric combined formulation DTaP–IPV/Hib vaccine. Expert Review of Vaccines, 2009, 8, 831-840.	4.4	19
83	Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clinical Infectious Diseases, 2020, 71, 1022-1029.	5.8	19
84	Approved but non-funded vaccines: Accessing individual protection. Vaccine, 2014, 32, 766-770.	3.8	18
85	The Epidemiology of Children Hospitalized With Herpes Zoster in Canada. Pediatric Infectious Disease Journal, 2008, 27, 112-118.	2.0	18
86	Safety and Immunogenicity of a Pentavalent Combination Vaccine (Diphtheria, Tetanus, Acellular) Tj ETQq0 0 0 15 to 18 Months of Age. Hum Vaccin, 2005, 1, 180-186.	rgBT /Ove 2.4	rlock 10 Tf 50 17
87	Ongoing Control of Haemophilus influenzae Type B Infections in Canadian Children, 2004–2007. Pediatric Infectious Disease Journal, 2008, 27, 755-757.	2.0	17
88	The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. Cmaj, 2011, 183, E1033-E1037.	2.0	17
89	Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine, 1995, 13, 104-108.	3.8	16
90	Assessment of Parent Education Methods for Infant Immunization. Canadian Journal of Public Health, 1997, 88, 405-408.	2.3	16

#	Article	IF	CITATIONS
91	Practical vaccination guidelines for children with cancer. Paediatrics and Child Health, 2001, 6, 379-383.	0.6	16
92	EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINE IN GREATER VANCOUVER, CANADA: 2004–2005. Pediatric Infectious Disease Journal, 2007, 26, 540-542.	2.0	16
93	Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e130-e134.	1.9	16
94	Hepatitis A vaccines: the growing case for universal immunisation of children. Expert Opinion on Pharmacotherapy, 2005, 6, 157-164.	1.8	15
95	Cellular Immunity as a Potential Cause of Local Reactions to Booster Vaccination With Diphtheria and Tetanus Toxoids and Acellular Pertussis Antigens. Pediatric Infectious Disease Journal, 2009, 28, 985-989.	2.0	15
96	Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given ASO3-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine, 2012, 30, 3389-3394.	3.8	15
97	Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Review of Vaccines, 2013, 12, 505-517.	4.4	15
98	Oculorespiratory Syndrome After Influenza Immunization in Children. Pediatric Infectious Disease Journal, 2005, 24, 63-69.	2.0	14
99	Do childhood vaccines cause thrombocytopenia?. Paediatrics and Child Health, 2009, 14, 31-32.	0.6	14
100	Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine. Vaccine Journal, 2013, 20, 459-467.	3.1	14
101	Reactogenicity to a Live Attenuated Varicella Vaccine in Canadian Children. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 97-102.	0.3	12
102	Comparative safety of tetanus-diphtheria toxoids booster immunization in students in Grades 6 and 9. Pediatric Infectious Disease Journal, 1998, 17, 1121-1126.	2.0	12
103	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1 <sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials, 2012, 13, 23-32.	2.0	12
104	Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Journal of Pediatrics, 1999, 135, 240-245.	1.8	11
105	Participant-collected, Mail-delivered Oral Fluid Specimens Can Replace Traditional Serosurveys. Canadian Journal of Public Health, 2007, 98, 37-40.	2.3	11
106	Invasive Pneumococcal Infections in Canadian Children, 1998–2003 Implications for New Vaccination Programs. Canadian Journal of Public Health, 2007, 98, 111-115.	2.3	11
107	Childhood immunization rates in Canada are too low: UNICEF. Paediatrics and Child Health, 2014, 19, 237-238.	0.6	11
108	Heterogeneity of Rotavirus Testing and Admitting Practices for Gastroenteritis among 12 Tertiary Care Pediatric Hospitals: Implications for Surveillance. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 15-18.	1.9	10

#	Article	IF	CITATIONS
109	Elevated Inflammatory Mediators in Adults with Oculorespiratory Syndrome following Influenza Immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study. Vaccine Journal, 2013, 20, 1108-1114.	3.1	10
110	A Randomized Study to Evaluate the Immunogenicity and Safety of a Heptavalent Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus influenzae b, and Meningococcal Serogroup C Combination Vaccine Administered to Infants at 2, 4 and 12 Months of Age. Pediatric Infectious Disease Journal, 2014, 33, 1246-1254.	2.0	10
111	Universal childhood hepatitis B vaccination: infants vs. preadolescents, the Canadian perspective. Pediatric Infectious Disease Journal, 1998, 17, S35-S37.	2.0	10
112	Reduced Susceptibility to Penicillin among Pneumococci Causing Invasive Infection in Children - Canada, 1991-1998. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 241-246.	0.3	9
113	Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial. Vaccine, 2012, 30, 4728-4732.	3.8	9
114	Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants. Vaccine, 2015, 33, 1897-1900.	3.8	9
115	New vaccines and the rising costs of caring. Paediatrics and Child Health, 2000, 5, 371-372.	0.6	8
116	Evaluation of Ready-to-use and Multi-dose Influenza Vaccine Formats in Large Clinic Settings. Canadian Journal of Public Health, 2000, 91, 329-332.	2.3	8
117	Hospital acquired rotavirus infections: burden in Canadian paediatric hospitals. Journal of Infection Prevention, 2011, 12, 159-162.	0.9	8
118	Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis. Vaccine, 2012, 30, 4023-4027.	3.8	8
119	Bacterial Endotoxins in Umbilical Cord Blood of Neonates. Neonatology, 1984, 45, 119-124.	2.0	7
120	Epidemiology of Meningococcal Disease in North America. , 2001, 67, 341-356.		7
121	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. Paediatrics and Child Health, 2002, 7, 645-648.	0.6	7
122	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 119-122.	2.0	7
123	Conforming to ICMJE principles. Cmaj, 2005, 173, 1358-1359.	2.0	7
124	Vaccination site reaction or bacterial cellulitis?. Paediatrics and Child Health, 2009, 14, 245-245.	0.6	7
125	SEVERE GENITAL ULCERATION IN AN ACUTE EPSTEIN-BARR VIRUS INFECTION. Pediatric Infectious Disease Journal, 2011, 30, 176-178.	2.0	7
126	Strategies for successful rapid trials of influenza vaccine. Clinical Trials, 2011, 8, 699-704.	1.6	7

#	Article	IF	CITATIONS
127	Will Infant Hepatitis B Vaccination Protect Into Adulthood?. Pediatric Infectious Disease Journal, 2017, 36, 609-615.	2.0	7
128	Prophylactic antibiotics in children. Pediatric Infectious Disease Journal, 1982, 1, 420-424.	2.0	6
129	ANTIGENURIA AFTER RECEIPT OF HAEMOPHILUS b DIPHTHERIA TOXOID CONJUGATE VACCINE. Pediatric Infectious Disease Journal, 1989, 8, 887.	2.0	6
130	Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications. Contemporary Clinical Trials, 2003, 24, 99-104.	1.9	6
131	A nationwide survey of past hepatitis A infections among Canadian adults. Vaccine, 2010, 28, 5174-5178.	3.8	6
132	Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 136-143.	3.3	6
133	High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. Journal of Clinical Immunology, 2014, 34, 655-662.	3.8	6
134	Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis. Human Vaccines and Immunotherapeutics, 2017, 13, 1254-1260.	3.3	6
135	Home-Testing for Recurrent Bacteriuria, Using Nitrite Strips. JAMA Pediatrics, 1978, 132, 46.	3.0	5
136	For coughs, colds and SARS, wear a mask. Paediatrics and Child Health, 2003, 8, 601-601.	0.6	5
137	Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada. Vaccine, 2013, 31, 5700-5705.	3.8	5
138	A comparative study of PENTAâ,,¢ vaccine booster doses given at 12, 15 or 18 months of age. Vaccine, 1999, 17, 543-550.	3.8	4
139	Population-Based Surveillance of HiB Invasive Infections in Children in British Columbia, Alberta and Ontario 1995 to 1997. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 135-140.	0.3	4
140	Immunologic Considerations for the Timing of the Booster Dose of 7-Valent Pneumococcal Conjugate Vaccine in Young Children. Pediatric Infectious Disease Journal, 2007, 26, 387-392.	2.0	4
141	Erythema Nodosum, Mycobacterium avium Lymphadenitis, and a 15-mm Mantoux Test. Pediatric Infectious Disease Journal, 2007, 26, 764-765.	2.0	4
142	Fever prophylaxis can reduce vaccine responses: A caution. Paediatrics and Child Health, 2018, 23, 245-246.	0.6	4
143	Dissenting Views on Dexamethasone Therapy for Bacterial Meningitis. Canadian Journal of Infectious Diseases & Medical Microbiology, 1994, 5, 201-202.	0.3	3
144	Pediatric investigators collaborative network on infections in Canada (PICNIC): The politics and positives of a cooperative study group. Journal of Clinical Epidemiology, 1997, 50, 495-497.	5.0	3

#	Article	IF	CITATIONS
145	Response to the changing epidemiology of meningococcal disease in North America 1945-2010. Human Vaccines and Immunotherapeutics, 2013, 9, 1323-1324.	3.3	3
146	Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings. Open Forum Infectious Diseases, 2016, 3, ofw187.	0.9	3
147	Hepatitis A vaccine: is it being used to best advantage?. Cmaj, 2002, 167, 44-5.	2.0	3
148	The Changing Face of Childhood Meningitis. Canadian Journal of Infectious Diseases & Medical Microbiology, 1994, 5, 58-59.	0.3	2
149	Population-Based Surveillance of Invasive Group A Streptococcal Disease in British Columbia: 1996-1998. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 232-236.	0.3	2
150	The Prevalence of Hepatitis A in Children in British Columbia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 175-179.	1.9	2
151	The Challenges Facing Canadian Trialists in an Increasingly Competitive Global Market: What Can be Done to Remain Competitive?. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 205-208.	1.9	2
152	Can children with minor illnesses be safely immunized?. Paediatrics and Child Health, 2011, 16, 463-463.	0.6	2
153	How best to describe the risk of meningococcal B infection?. Paediatrics and Child Health, 2013, 18, 543-544.	0.6	2
154	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. Paediatrics and Child Health, 2002, 7, 645-8.	0.6	2
155	Staphylococcus epidermidis-associated enterocolitis. Journal of Pediatrics, 1987, 110, 330.	1.8	1
156	Evaluation ofHaemophilus influenzaeType B Conjugate Vaccine (Meningococcal Protein Conjugate) in Canadian Infants. Canadian Journal of Infectious Diseases & Medical Microbiology, 1994, 5, 75-81.	0.3	1
157	The burden of pneumococcal infections in children. Paediatrics and Child Health, 2001, 6, 5B-8B.	0.6	1
158	Questions and answers on immunization. Paediatrics and Child Health, 2007, 12, 317-318.	0.6	1
159	Does vaccination with the varicella vaccine within four weeks after the measles, mumps and rubella vaccine reduce protection?. Paediatrics and Child Health, 2009, 14, 501-501.	0.6	1
160	Optimizing Canadian Public Immunization Programs: A Prescription for Action. Canadian Journal of Public Health, 2011, 102, 193-195.	2.3	1
161	Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 591-597.	2.9	1
162	Discussing the need for an adolescent hepatitis B vaccine booster in infant vaccinees. Paediatrics and Child Health, 2014, 19, 404-404.	0.6	1

#	Article	IF	CITATIONS
163	Do Dose Numbers Matter?. Pediatric Infectious Disease Journal, 2016, 35, 1242-1246.	2.0	1
164	Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine, 2017, 35, 5019-5026.	3.8	1
165	Will Infant Hepatitis B Immunization Protect Adults?. Pediatric Infectious Disease Journal, 2019, 38, S64-S66.	2.0	1
166	Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1. Emerging Infectious Diseases, 2020, 26, 454-462.	4.3	1
167	HOW TO INCREASE BY 40% THE NUMBER OF PEDIATRIC DOSES RECOVERED FROM MULTIDOSE VIALS OF HEPATITIS B VACCINES. Pediatric Infectious Disease Journal, 1999, 18, 560-561.	2.0	1
168	How long can we expect pertussis protection to last after the adolescent booster dose of tetanus-diphtheria-pertussis (Tdap) vaccines?. Paediatrics and Child Health, 2007, 12, 873-4.	0.6	1
169	The contribution of coagulase-negative staphylococci to neonatal necrotizing enterocolitis. Infectious Diseases Newsletter (New York, N Y ), 1988, 7, 4-5.	0.4	0
170	A Perspective on Vaccine Evaluation Research in Canada: Past and Future. Canadian Journal of Infectious Diseases & Medical Microbiology, 1993, 4, 79-83.	0.3	0
171	Where is the Varicella Vaccine?. Canadian Journal of Infectious Diseases & Medical Microbiology, 1996, 7, 179-180.	0.3	0
172	On caring and counting. Paediatrics and Child Health, 1998, 3, 221-221.	0.6	0
173	Random Gleanings from the Literature. Paediatrics and Child Health, 2001, 6, 199-199.	0.6	Ο
174	Pneumococcal disease: Implications in paediatrics. Paediatrics and Child Health, 2001, 6, 4B-4B.	0.6	0
175	Practical questions and answers about childhood immunization. Paediatrics and Child Health, 2004, 9, 476-476.	0.6	0
176	Questions and answers on immunization. Paediatrics and Child Health, 2005, 10, 423-423.	0.6	0
177	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. Paediatrics and Child Health, 2006, 11, 413-415.	0.6	0
178	Regrettable lack of definition of the "well tolerated―vaccine. Vaccine, 2010, 28, 3755-3756.	3.8	0
179	Preparedness for and Response to Meningococcal Outbreaks: Safety Results. of a Randomized Controlled Trial of Two Schedules of 4CMenB Vaccine in Adolescents and Young Adults. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
180	DOES TREATMENT WITH DEXAMETHASONE AFFECT THE IMMUNOLOGICAL RESPONSE TO ANTIGENIC CHALLENGE OF INFANTS BORN PRETERM? 1717. Pediatric Research, 1996, 39, 289-289.	2.3	0

#	Article	IF	CITATIONS
181	Genotyping of Penicillin-Highly Resistant Invasive Streptococcus pneumoniae Obtained from Canadian Children Early in the Resistance Epidemic. Pediatric Research, 1999, 45, 161A-161A.	2.3	0
182	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. Paediatrics and Child Health, 2006, 11, 413-5.	0.6	0